Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
X
X
publication

Polyclonal Heterogeneity: The New Norm for Secondary Clinical Resistance to Targeted Monotherapy in Relapsed Leukemia?


Wei, A.H. et al.
Cancer Discovery (2019)
Abstract

In this issue, McMahon and colleagues demonstrate that secondary clinical resistance to the FLT3 inhibitor gilteritinib in relapsed acute myeloid leukemia is often polyclonal and commonly mediated by heterogeneous mutations that activate downstream RAS-MAPK pathways. These findings and recent data from others indicate that emergence of multiple clones, each with distinct mechanisms of resistance, is a common finding at secondary failure of single-agent-targeted therapies for relapsed leukemias..



Authors

Wei, A.H., Roberts, A.W.



VIEW

publication
Clonal evolution and heterogeneity in advanced systemic mastocytosis revealed by single-cell DNA sequencing
Lim, K.
Blood Advances
publication
Joint profiling of DNA and proteins in single cells to dissect genotype-phenotype associations in leukemia
Demaree, B.
Nature Communications
publication
Single-cell DNA sequencing reveals complex mechanisms of resistance to quizartinib
Peretz, C.A.C
Blood Advances (2021)
publication
Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome
Alyssa L. Kennedy
Nature Communications (2021)